black smithkline is partnering with the national institutes of health to conduct the tests. >>> could north korea be softening? coming up, an american hostage there is heading home after an appeal from president obama. >> while prices at the pump are on the decline, it appears airline prices are taking off. coming up, find out how much more you'll probably spend getting to your holiday destination. >> also ahead... >> reporter: i'm investigative reporter russ ptacek. coming up, a shutdown at a motel with health code violations. >>> north korea's release of an american hostage is fueling new hope two other americans will also be freed. jeffrey fowle is back home in ohio after being freed early tuesday. the state department is still trying to free americans matthew miller and kenneth bae. bae, the longest held american prisoner since the korean war remains in a labor camp. miller, one of the most recent prisoners, is also being held. >>> let's go -- it's going to cost you more to hop on a plane this holiday season. expedia.com says airline tickets sales for thanksgiving weekend are up 1

researchers are testing two potential vaccines from glaxo smithkline and new link genetics. >>> countc 10 to help ease your concerns about the ebola virus. monday morning we'll have two medical professionals right here at the nbc 10 studios answering your questions. if you have a question, send it right now. logon to the nbc 10 facebook page and look for the ebola q & a section. >>> a philadelphia man will serve prison time for pleading guilty to placing an ad on craigslist for h omosexual sex. >>> new information tonight about a local lawmaker accused of using her elected office for political and financial gain. >> he's going to plead guilty to the charges. >> as of now, that's correct, yes. >> that's the attorney for leanna washington confirming to nbc 10's deanna durante that the pennsylvania state senator will plead guilty next week. he wouldn't say what the exact terms of the negotiated plea are. the 69-year-old democrat is facing felony charges for allegedly using her taxpayer paid staff to plan and perform political activities. washington lost her re-election bid in the may pri

. >>> well, one pharmaceutical giant working on developing a vaccine is grabbi galaxo smithkline.s summer after the worst ebola outbreak ever hit three countries in west africa, the world health organization asked galaxo to fast-track human trials for emergency use. donna joins us now from philadelphia. donna this is something that everybody is suddenly very interested in. you heard in mary's story that generally speaking, pharmaceutical companies focus on diseases that will be present in the west. where are we can an ebola treatment? >> well, right now we are still in the phase i trials. that started in the beginning of september. they did ask jfk if we would now move into human trials. so there are four trials planned, three of which have started. two trials started in the u.s., sponsored for the national institutes for health, and another trial involving 60 people started at oxford university. we plan to do two more countries in west africa. >> and tell me about these trials. how long are they? and do you have to finish these two, before you start the other two? or can they go

getting some traction right now is one developed at the research center at niac in conjunction with smithkline based on the chimp adenovirus with the ebola protein gene inserted along with the sudan gene. in nonhuman primates immunized in anticipation of infection 100% effective and it is now in phase one testin testing in this country. they vector itself has been in over 200 subjects in the ebola like protein vaccine has now been in 80 subjects in the phase e study which is being conducted and will eventually have 200 people. the company projects 15,000 doses of the monovalent vaccine to be available in december and minus 80 degrees and known to be stable for a time at minus 20. the other vaccine which is getting a lot of attention is one based on a virus. the same idea the glycoprotein is traded for the glycoprotein of ebola. it was actually developed 10 years ago at the public health agency of canada and now is licensed for breyer put -- bioprotection. it is effective as a single do dose. it's a general use vaccine meant to be protected by 100% within 21 days and there is some data that sug

. >> we have a question from a doctor in the audience reports from who and glaxo smithkline indicate the likelihood that the epidemic will be over before the vaccine to be licensed for efficacy this been a guy cannot comment on someone else's pronouncement i did not hear that but if that was said i would say right now i do think we can predict when the epidemic will be over it is still escalating as opposed to declining. so it is not very prudent to predict when it will end i think the best way is to make sure that we as a global community put in sufficient resources. >> is their concern about the blood supply at all? now here in america? >> in this country? >> i think at this point there are few cases that can be clearly identified and is not with blood donors i know the fda will keep an eye on this. >> how important in the media's role is? what can the media do better? >> and our area is has done a good job and a critical role to tell the facts there so many rumors how hard it is to be transmitted in a casual setting but the a break is a beer in west africa to work together. it is

>> we have seen some precedent with helping each other, and that includes not only >> smithkline, butzer and other companies that are bringing the production capabilities to their. we -- to bear. we are discussing it as we speak to accelerate more than we are today. once you are meeting with, talking to the chief scientific officer said his other countries? >> yes, and alex is talking to all of the ceos, so we will make sure everyone is working together to get the possible ash best possible results. -- best possible results. >> given the resources, time, and effort that j&j is pouring into the research for an ebola vaccine, what do you have to back burner as a result? >> nothing. the engagement you get is fantastic as everyone will put in the extra hours on top of what we do today. there will be no impact on any of our other programs. our team is very dedicated, very encouraged. , the 125,000&j employees, all are committing part of their time on top of what they do normally for the company. i wouldn't worry about that. >> now, you're looking for a vaccine, which would help to protect